3, 2015 /PRNewswire/ --Summary Global Markets Direct's, 'Pneumocystis
Infection - Pipeline Review, H2 2015', provides an overview of the Pneumocystis
Infection's therapeutic pipeline.
Describe presentations of Pneumocystis
jirovecii pneumonia, based on a prospective, multicenter observational study in France
jiroveci is an opportunist pathogen that causes critical and life-threatening infection in immunocompromised patients with hematologic malignancies, organ transplants, connective tissue diseases, or human immunodeficiency virus (HIV) type 1 infection.
Revised and updated, this edition has a new chapter on infections caused by Pneumocystis
Since the introduction of antiretroviral therapy (ART) for individuals who are HIV-infected with AIDS, there has been a dramatic decline in the number of these patients presenting with Pneumocystis
jerovicii pneumonia (PcP) in the developed world.
On June 5, 1981, an article concerning five previously healthy, young gay men in Los Angeles diagnosed with Pneumocystis
carinii pneumonia, an infection that usually appears only in individuals with substantial immune system damage, appeared in the Morbidity and Mortality Weekly Report, a publication of the Centers for Disease Control and Prevention.
is attributed to the June 5, 1981, report by the Centers for Disease Control and Prevention (CDC) describing the unusual occurrence of Pneumocystis
pneumonia in five homosexual men in Los Angeles.
Given the concern for PCP, patient underwent bronchoscopy and broncho-alveolar lavage (BAL) revealed numerous Pneumocystis
carinii organisms on gram stain.
In postmarketing studies of infliximab, rates of Pneumocystis
pneumoniae in Japanese patients with rheumatoid arthritis were found to be higher (at 0.
Background & objectives: Pneumocystis
jiroveci (also known as P.
The assay, FXGTM: RESP (Asp +), uses Real-Time PCR technology to accurately and rapidly identify infections caused by both Aspergillus and Pneumocystis
Adjunctive corticosteroid treatment of clinical Pneumocystis
jiroveci pneumonia in infantsless than 18 months of age--a randomised controlled trial.